PT  - JOURNAL ARTICLE
AU  - Tagai, Kenji
AU  - Ono, Maiko
AU  - Kubota, Manabu
AU  - Kitamura, Soichiro
AU  - Takahata, Keisuke
AU  - Seki, Chie
AU  - Takado, Yuhei
AU  - Shinotoh, Hitoshi
AU  - Sano, Yasunori
AU  - Matsuoka, Kiwamu
AU  - Takuwa, Hiroyuki
AU  - Shimojo, Masafumi
AU  - Takahashi, Manami
AU  - Kawamura, Kazunori
AU  - Kikuchi, Tatsuya
AU  - Okada, Maki
AU  - Akiyama, Haruhiko
AU  - Suzuki, Hisaomi
AU  - Onaya, Mitsumoto
AU  - Takeda, Takahiro
AU  - Arai, Kimihito
AU  - Arai, Nobutaka
AU  - Araki, Nobuyuki
AU  - Saito, Yuko
AU  - Kimura, Yasuyuki
AU  - Ichise, Masanori
AU  - Tomita, Yutaka
AU  - Zhang, Ming-Rong
AU  - Suhara, Tetsuya
AU  - Shigeta, Masahiro
AU  - Sahara, Naruhiko
AU  - Higuchi, Makoto
AU  - Shimada, Hitoshi
TI  - High-contrast in-vivo imaging of tau pathologies in Alzheimer’s and non-Alzheimer’s disease tauopathies
AID  - 10.1101/2020.03.05.20028407
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.03.05.20028407
4099  - http://medrxiv.org/content/early/2020/05/18/2020.03.05.20028407.short
4100  - http://medrxiv.org/content/early/2020/05/18/2020.03.05.20028407.full
AB  - A panel of radiochemicals has enabled in-vivo positron emission tomography (PET) of tau pathologies in Alzheimer’s disease (AD), while sensitive detection of frontotemporal lobar degeneration (FTLD) tau inclusions has been unsuccessful. Here, we generated an imaging probe, PM-PBB3, for capturing diverse tau deposits. In-vitro assays demonstrated the reactivity of this compound with tau pathologies in AD and FTLD. We could also utilize PM-PBB3 for optical/PET imaging of a living murine tauopathy model. A subsequent clinical PET study revealed increased binding of 18F-PM-PBB3 in diseased patients, reflecting cortical-dominant AD and subcortical-dominant PSP tau topologies. Notably, the in-vivo reactivity of 18F-PM-PBB3 with FTLD tau inclusion was strongly supported by neuropathological examinations of autopsied and biopsied brains derived from Pick’s disease, PSP and corticobasal degeneration patients who underwent PET scans. Finally, visual inspection of 18F-PM-PBB3-PET images was indicated to facilitate individually based identification of diverse clinical phenotypes of FTLD on the neuropathological basis.Competing Interest StatementM-R. Zhang, T. Suhara, M. Higuchi, and H. Shimada hold a patent on compounds related to the present report (JP 5422782/EP 12 884 742.3/CA2894994/HK1208672). All the other authors have no potential conflicts of interest to be disclosed.Clinical TrialUMIN-CTR; number 000030248Funding StatementThis study was supported in part by AMED under Grant Number JP18dm0207018, JP19dm0207072, JP18dk0207026, JP19dk0207049 to M. H., and by MEXT KAKENHI Grant Number JP16H05324 to M. H., JP18K07543 to H. Shimada, JP26117011 to N. S., and by JST CREST Grant Number JPMJCR1652 to M. Higuchi.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe authors confirm that the data supporting the findings of this study are available within the article and its supplementary materials.